Lymphoma & Myeloma Clinical Trials
Last Updated: 06/11/2025
CAR T Cellular Therapy
Lymphoma CAR T Cell Therapy
Previously Untreated
2022-0463 An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Previously Treated
2021-0468 Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL, DLBCL and ALL
2020-1136 A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
A Phase 1 multicenter study evaluating the safety and efficacy of ACE1831, an Allogeneic CD20-Conjugated Gamma Delta T-Cell therapy, In adult subjects with relapsed/refractory CD20-expressing B-Cell malignancies
Expanded access protocol for patients receiving lisocabtagene maraleucel that is nonconforming for commercial release
Myeloma CAR T Cell Therapy
None at this time
Lymphoma Clinical Trials
Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)
Previously Untreated
A phase 3, multicenter, randomized, open-label trial to evaluate the safety and efficacy of Epcoritamab + Rituximab and Lenalidomide (R^2 ) compared to chemoimmunotherapy in previously untreated follicular lymphoma (EPCORE FL-2).
2024-0385 Randomized Phase III Study of Mosunetuzumab Vs. Rituximab for Low Tumor Burden Follicular Lymphoma
2023-0063 Phase 2 trial of Obinutuzumab and CC-99282 for patients with previously untreated high tumor burden follicular lymphoma
2022-0938 A phase 1 study of JV-213 autologous CD79b-targeting chimeric antigen receptor T-cell therapy in adults with relapsed or refractory B cell lymphomas
2023-0087 A phase II study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, in combination with radiotherapy (RT) in relapsed/refractory indolent non-Hodgkin lymphoma
Previously Treated
A phase 2 trial of mosunetuzumab and zanubrutinib for patients with relapsed/refractory marginal zone lymphoma
Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.
A Phase lb, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, And Efficacy of Mosunetuzumab or Glofitamab In Combination With CC-220 And CC-99282 In Patients With B-Cell Non-Hodgkin Lymphoma
2021-0091 A Multicenter, Phase1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-cell Non Hodkins Lymphoma
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2022-0551 A phase 1/2, open-label study of Valemetostat in combination with Rituximab and Lenalidomide in relapsed or refractory Follicular Lymphoma
2023-0335 A phase 3 randomized, open-label, multicenter study of Zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus Lenalidomide Plus Rituximab in patients with Relapsed/Refractory follicular or marginal zone lymphoma
2022-0459 A phase II trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in patients with relapsed B-cell NHL
2019-1250 A Phase 2, Open-Label, Single-Arm, Multi Cohort, Multi-Center Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHLl)
2024-0115 A Phase 3, Randomized, Open-Label StudyComparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma
Aggressive Lymphoma (Large B cell Lymphoma, Diffuse Large B cell Lymphoma, Burkitt's Lymphoma)
Newly diagnosed
2020-0686 A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-cell Lymphoma
2023-0031 Phase 2 trial of Epcoritamab in combination with Rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell Lymphoma.
Previously Treated
2024-0431 A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3)
2023-0673 A phase 2 Study of Axicabtagene Ciloleucel and Glofitamab as second-line therapy for relapsed or refractory, or high-risk untreated patients with large B Cell Lymphoma
Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients with Large B-cell Lymphoma who Achieve Partial Remission After CAR T-cell Therapy
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2020-1041 A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
2020-1169 A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
2022-0602 An Open-Label, Phase I Study To Evaluate The Safety, Pharmacokinetics And Preliminary Antitumor Activity Of Ro7227166 (A Cd19 Targeted 4-1bb Ligand) In Combination With Obinutuzumab And In Combination With Glofitamab Following A Pretreatment Dose Of Obinutuzumab Administered In Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
2023-0274 A Randomized, Open-Label, Multicenter Phase Iii Study Evaluating Efficacy And Safety Of Mosunetuzumab In Combination With Polatuzumab Vedotin In Comparison With Rituximab In Combination With Gemcitabine Plus Oxaliplatin In Participants With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
2024-1549 A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies
Previously Treated Burkitt Lymphoma
2022-0938 A phase 1 study of JV-213 autologous CD79b-targeting chimeric antigen receptor T-cell therapy in adults with relapsed or refractory B-cell lymphomas
Mantle Cell Lymphoma
Newly Diagnosed
2023-0413 Phase II study of Pirtobrutinib, rituximab (PR) in previously untreated low and intermediate risk MCL (mantle cell lymphoma) patients
2024-0220 GATE1: A multicenter phase II study of pirtobrutinib, rituximab and venetoclax combination therapy for patients with previously untreated mantle cell lymphoma
Previously Treated
Tafasitamab, Lenalidomide and Venetoclax combination therapy for relapsed or refractory Mantle Cell Lymphoma (V-MIND)
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
2025-0045 A phase 3 randomized double-blind multicenter study of sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib in patients with relapsed/refractory mantle cell lymphoma
2024-1726 Phase 1 trial of BTM-3566 in relapsed/refractory mature B Cell Lymphomas.
Hodgkin Lymphoma
Newly Diagnosed
2022-1065 NCI10590: NORM: nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase 2 trial with either Rituximab or Mosunetuzumab
Previously Treated
A phase 1 first in human study of ARV-393 in adult participants with advanced Non-Hodgkin's Lymphoma
2022-1065 NCI10590: NORM: nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase 2 trial with either Rituximab or Mosunetuzumab
2021-1033 An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma
T-Cell Lymphoma
Newly Diagnosed
A phase 3, randomized, open-label study comparing the efficacy and safety of the combination of Beleodaq-CHOP or Folotyn-COP to the CHOP regimen alone in newly diagnosed patients with peripheral T cell lymphoma.
Previously Treated
2023-0962 A phase 3, randomized, open-label study to investigate the efficacy and safety of ITK inhibitor Soquelitinib versus physician's choice standard of care treatment (Selected Single Agent) in participants with Relapsed/Refractory peripheral T-cell Lymphoma not otherwise specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
2017-0927 A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas
2021-1033 An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma
Untreated Peripheral T-Cell Lymphoma
2024-0517 A Phase II, Single-Center, Single-Arm Study Evaluating The Safety And Efficacy Of Golidocitinib In The Management Of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study)
Previously Treated Peripheral T-Cell Lymphoma
2022-0437 A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
2024-0198 A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Multiple Myeloma Clinical Trials
Newly Diagnosed
2024-0003 Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
SWOG S2209: A phase III randomized trial for newly diagnosed Multiple Myeloma (NDMM) patients considered frail or in a subset of "intermediate fit" comparing upfront three-drug induction regimens followed by double- or single-agent maintenance.
2021-0191 (DETER-SMM) EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
2020-0431 A Phase 1 with Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
2023-0363 Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in previously untreated patients with symptomatic multiple Myeloma (Linker-MM4 Study)
PA19-0436 Molecular Monitoring of Myeloma Response and Resistance mechanisms: NDMM - tx na?ve; planning on frontline therapy that contains PI and/or IMiD
2023-0322 A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing
Previously Treated
2024-1162 A phase 1b/2 study of GC012F (AZD0120), a chimeric antigen receptor T-cell (CAR T) therapy targeting CD19 and B-cell maturation antigen (BCMA) in subjects with relapsed/refractory multiple myeloma
2023-0502 A phase 1, multicenter, open-label study to evaluate the safety and preliminary efficacy of BMS-986393 in novel combinations in participants with relapsed and/or refractory multiple myeloma and determine the recommended dose for each add-on investigational component
2023-0719 A phase 3, two-stage, randomized, multicenter, open-label study comparing Mezigdomide(CC-92480), Bortezomib and Dexamethasone (MeziVd)versus Pomalidomide,Bortezomib and Dexamethasone (PVD) in subjects with Relapsed or Refractory Multiple myeloma (RRMM): successor-1
2023-0527 Phase I/II open label study of Belumosudil Mesylate alone, and in combination with Dexamethasone, in patients with relapsed/refractory multiple myeloma
2024-1148 A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
2021-0185 A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP -101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
2023-0420 Phase 1/2 study of IDP 023 as a single agent and in combination with antibody therapies in patients with advanced Hematologic cancers.
2023-1048 A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
2023-0171 Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered with NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
2024-0003 Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
2024-1162 A Ph 1b/2 study of GC012F in subjects with relapsed/refractory multiple myeloma
Waldenstrom¡¯s Previously Treated
2023-0106 First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies
AL Amyloid
2024-1019 SWOG: Study S2213 a phase III, randomized study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DaraVCD)
Induction followed by Autologous Stem Cell Transplant or Dara-VCD consolidation and Daratumumab maintenance in patients with newly diagnosed AL Amyloidosis
2024-0160 A phase 1/2 study of linvoseltamab in patients with relapsed or refractory systemic light chain amyloidosis
Untreated SGUS/SMM
PA15-0575 Observational prospective research study in monoclonal Gammopathies leadINg to myeloma (ORIGIN study)
2016-0172 Quality of Life in Patients with Asymptomatic Monoclonal Gammopathies (MGUS/SMM)
2021-0191 EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
2020-0431 A Phase 1 with Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (BELLA)
Laboratory Studies
PA18-1073 Pilot study of the validation of as single cell proteopenomic assay in multiple myeloma and its precursor stages (PCL / LPL)
PA19-0436 Molecular Monitoring of Myeloma Response and Resistance mechanisms: NDMM - tx na?ve; planning on frontline therapy that contains PI and/or IMiD
2021-0440 A Collection of Blood and Tissue Samples from Patients with Amyloidosis and/or Monoclonal Gammopathies (including Lymphoplasmacytic Lymphoma) and Normal Donors
Other Clinical Trials
An open-label, dose escalation and dose expansion trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with relapsed or refractory primary central nervous system lymphoma
A phase 1/2 study of linvoseltamab in patients with relapsed or refractory systemic light chain amyloidosis
2023-0942 Study of AZD3470 in participants with relapsed/refractory hematologic malignancies
2023-0864 A pilot study of Emapalumab for the treatment of CAR T-Cell therapy-associated prolonged cytopenia
An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies
2023-0581 A randomized trial of fecal microbiota transplantation for remedying antibiotics-induced microbiota dysbiosis in lymphoma patients receiving Axicabtagene Ciloleucel therapy
PA15-0575 Observational prospective research study in monoclonal Gammopathies leadINg to myeloma (ORIGIN study)
A Multicenter, Open-label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma with or without HIV
2022-0396 Feasibility of Combined Genomics/Transcriptomics for Patients with Lymphoma
2021-0440 A Collection of Blood and Tissue Samples from Patients with Amyloidosis and/or Monoclonal Gammopathies (including Lymphoplasmacytic Lymphoma) and Normal Donors
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
2022-0918 Expanded access study for the treatment of patients with commercially out-of-specification Axicabtagene Ciloleucel
2023-0420 Phase 1/2 study of IDP 023 as a single agent and in combination with antibody therapies in patients with advanced Hematologic cancers.